Neurology

HR+

Questions discussed in this category

How would you manage adjuvant endocrine therapy for a postmenopausal patient with early stage HR+ breast CA who develops an ischemic CVA on an AI?

Presuming that work-up for cardioembolic sources is negative, how would you proceed?

1 Answer available

Papers discussed in this category

Circulation, 2020 Feb 17

Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.

Related Topics in Neurology